Literature DB >> 32945994

COH outcomes in breast cancer patients for fertility preservation: a comparison with the expected response by age.

Elisa Malacarne1, Marta Devesa2, Francisca Martinez2, Ignacio Rodriguez2, Buenaventura Coroleu2.   

Abstract

PURPOSE: Breast cancer is the most common cancer diagnosed during childbearing age, and fertility preservation is becoming increasingly more essential. However, recent studies indicate a possible poorer response to controlled ovarian hyperstimulation (COH) in cancer patients than in non-cancer controls and a negative impact of BRCA mutations on female fertility. This study aims to evaluate ovarian response and the number of mature oocytes (MII) vitrified in women with breast cancer, with or without BRCA mutation, comparing them to the expected response according to an age-related nomogram.
METHODS: This is a retrospective observational study involving sixty-one breast cancer patients who underwent COH for oocyte cryopreservation. The age-specific nomogram was built using 3871 patients who underwent COH due to oocyte donation, fertility preservation for non-medical reasons, or FIVET for male factor exclusively.
RESULTS: The mean number of oocytes retrieved was 13.03, whereas the mean number of MII oocytes was 10.00. After the application of the z-score, no statistically significant differences were found compared with the expected response in the general population, neither by dividing patients according to the presence or absence of BRCA mutation nor according to the phase in which they initiated stimulation.
CONCLUSION: The results obtained do not support the notion of a negative impact of the BRCA mutation on the ovarian response of women with breast cancer. Women with breast cancer undergoing COH for fertility preservation can expect the ovarian response predicted for their age.

Entities:  

Keywords:  BRCA; Breast Cancer; Controlled ovarian hyperstimulation; Fertility preservation; Nomogram; Ovarian response

Mesh:

Substances:

Year:  2020        PMID: 32945994      PMCID: PMC7714818          DOI: 10.1007/s10815-020-01944-x

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  32 in total

1.  Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment.

Authors:  Javier Domingo; Vicente Guillén; Yanira Ayllón; María Martínez; Elkin Muñoz; Antonio Pellicer; Juan A Garcia-Velasco
Journal:  Fertil Steril       Date:  2012-01-28       Impact factor: 7.329

2.  Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Authors:  Kutluk Oktay; Brittany E Harvey; Ann H Partridge; Gwendolyn P Quinn; Joyce Reinecke; Hugh S Taylor; W Hamish Wallace; Erica T Wang; Alison W Loren
Journal:  J Clin Oncol       Date:  2018-04-05       Impact factor: 44.544

3.  Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results.

Authors:  Christine Decanter; Franck Morschhauser; Pascal Pigny; Catherine Lefebvre; Cécile Gallo; Didier Dewailly
Journal:  Reprod Biomed Online       Date:  2009-12-03       Impact factor: 3.828

4.  Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer.

Authors:  Joseph M Letourneau; Erin E Ebbel; Patricia P Katz; Kutluk H Oktay; Charles E McCulloch; Wei Z Ai; A Jo Chien; Michelle E Melisko; Marcelle I Cedars; Mitchell P Rosen
Journal:  Cancer       Date:  2011-08-17       Impact factor: 6.860

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

6.  American Society of Clinical Oncology recommendations on fertility preservation in cancer patients.

Authors:  Stephanie J Lee; Leslie R Schover; Ann H Partridge; Pasquale Patrizio; W Hamish Wallace; Karen Hagerty; Lindsay N Beck; Lawrence V Brennan; Kutluk Oktay
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

Review 7.  Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Alison W Loren; Pamela B Mangu; Lindsay Nohr Beck; Lawrence Brennan; Anthony J Magdalinski; Ann H Partridge; Gwendolyn Quinn; W Hamish Wallace; Kutluk Oktay
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

8.  Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients.

Authors:  Whoon Jong Kil; Seung Do Ahn; Seong Soo Shin; Sang-Wook Lee; Eun Kyung Choi; Jong Hoon Kim; Byung Ho Son; Sei-Hyun Ahn; Woo Kun Kim; Sung Bae Kim
Journal:  Breast Cancer Res Treat       Date:  2006-03-23       Impact factor: 4.872

9.  The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer.

Authors:  R A Anderson; A P N Themmen; A Al-Qahtani; N P Groome; D A Cameron
Journal:  Hum Reprod       Date:  2006-07-04       Impact factor: 6.918

10.  Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives.

Authors:  Francisca Martinez
Journal:  Hum Reprod       Date:  2017-09-01       Impact factor: 6.918

View more
  1 in total

1.  In vitro maturation of immature oocytes for fertility preservation in cancer patients compared to control patients with fertility problems in an in vitro fertilization program.

Authors:  Irma Virant-Klun; Jure Bedenk; Nina Jancar
Journal:  Radiol Oncol       Date:  2021-12-22       Impact factor: 2.991

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.